The Latest Breaking News from ADMA

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency.

ADMA stock hit a new buy point in recent weeks after recovering from an unexpected plunge that sent shares below a key level.

Benzinga Pro data, ADMA Biologics (NASDAQ:ADMA) reported Q1 sales of $29.10 million. Earnings fell to a loss of $25.01 million, resulting in a 50.2% decrease from last quarter.

ADMA Biologics (NASDAQ:ADMA) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings ADMA Biologics missed estimated earnings by 25.0%, reporting an EPS of $-0.1 versus an estimate of $-0.08.

ADMA Biologics (NASDAQ:ADMA) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that ADMA Biologics will report an earnings per share (EPS) of $-0.08.

According to data from Benzinga Pro, during Q4, ADMA Biologics's (NASDAQ:ADMA) reported sales totaled $26.38 million. Despite a 6.0% increase in earnings, the company posted a loss of $16.65 million.

ADMA Biologics Inc (NASDAQ: ADMA) closed a debt refinancing with Hayfin Capital Management of $150 million, and up to an additional $25 million tied to specific revenue targets during 2022.

ADMA Biologics (NASDAQ:ADMA) is set to give its latest quarterly earnings report on Thursday, 2022-03-24. Here's what investors need to know before the announcement. Analysts estimate that ADMA Biologics will report an earnings per share (EPS) of $-0.09.

ADMA Biologics Inc (NASDAQ: ADMA) expects